The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety data from a phase II randomized trial of radium-223 dichloride (Ra-223) plus enzalutamide (Enza) vs. Enza alone in men with metastatic castration refractory prostate cancer (mCRPC).
 
Benjamin Louis Maughan
Consulting or Advisory Role - Janssen Oncology
 
John M. Hoffman
No Relationships to Disclose
 
Kathryn Morton
No Relationships to Disclose
 
Bhasker Koppula
No Relationships to Disclose
 
Julia Anne Batten
No Relationships to Disclose
 
Jared Thorley
No Relationships to Disclose
 
Josiah Hawks
No Relationships to Disclose
 
Kenneth Boucher
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)